CatalystAlertBeta

Loading market movers...

Aldeyra Therapeutics, Inc.

ALDX

$313M

Small Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaLEXINGTON8 employees

Drugs in Pipeline

19

Phase 3 Programs

10

Upcoming Catalysts

0

Next Catalyst

None scheduled

Market Overview

Stock performance and key metrics

ALDX News

Catalyst Timeline

1 upcoming, 1 past

PDUFANext

FDA PDUFA Date reproxalap (standard)

Mar 17, 2026Confirmed

For dry eye disease. NDA filing. Extracted from SEC filing: 8-K

Drug Pipeline

Reproxalap Ophthalmic Solution (0.25%)

Dry Eye Syndromes

Vehicle Ophthalmic Solution

Dry Eye

Vehicle Opthalmic Solution

Dry Eye

ADX-102 1% Topical Dermal Cream (reproxalap)

Sjogren-Larsson Syndrome

ADX-2191 (intravitreal methotrexate 0.8%)

Proliferative Vitreoretinopathy

Vehicle of ADX-102 Ophthalmic Solution

Non-infectious Anterior Uveitis

Reproxalap Ophthalmic Solution (0.25%) QID

Dry Eye

Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID

Dry Eye

ADX-102 Ophthalmic Solution (0.5%)

Dry Eye Syndromes

Reproxalap Ophthalmic Solution (0.5%)

Allergic Conjunctivitis

ADX-102 Ophthalmic Drops (0.5%)

Conjunctivitis, Allergic

ADX-2191

Retinitis Pigmentosa

ADX-629

Ethanol Intoxication

Active topical NS2 1% dermatologic cream

Sjögren-Larsson Syndrome

ADX-629 (Open-label)

Atopic Dermatitis

Xiidra® (5% lifitegrast ophthalmic solution)

Dry Eye

NS2 Ophthalmic Drops (0.5%)

Allergic Conjunctivitis

NS2

Non-infectious Anterior Uveitis

Reproxalap Ophthalmic Solution (0.1%)

Dry Eye Syndrome

Drug Name	Phase	Indication	Designations	Patent
Reproxalap Ophthalmic Solution (0.25%)	Phase 3	Dry Eye Syndromes	-	-
Vehicle Ophthalmic Solution	Phase 3	Dry Eye	-	-
Vehicle Opthalmic Solution	Phase 3	Dry Eye	-	-
ADX-102 1% Topical Dermal Cream (reproxalap)	Phase 3	Sjogren-Larsson Syndrome	-	-
ADX-2191 (intravitreal methotrexate 0.8%)	Phase 3	Proliferative Vitreoretinopathy	-	-
Vehicle of ADX-102 Ophthalmic Solution	Phase 3	Non-infectious Anterior Uveitis	-	-
Reproxalap Ophthalmic Solution (0.25%) QID	Phase 3	Dry Eye	-	-
Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID	Phase 3	Dry Eye	-	-
ADX-102 Ophthalmic Solution (0.5%)	Phase 3	Dry Eye Syndromes	-	-
Reproxalap Ophthalmic Solution (0.5%)	Phase 3	Allergic Conjunctivitis	-	-
ADX-102 Ophthalmic Drops (0.5%)	Phase 2	Conjunctivitis, Allergic	-	-
ADX-2191	Phase 2	Retinitis Pigmentosa	-	-
ADX-629	Phase 2	Ethanol Intoxication	-	-
Active topical NS2 1% dermatologic cream	Phase 2	Sjögren-Larsson Syndrome	-	-
ADX-629 (Open-label)	Phase 2	Atopic Dermatitis	-	-
Xiidra® (5% lifitegrast ophthalmic solution)	Phase 2	Dry Eye	-	-
NS2 Ophthalmic Drops (0.5%)	Phase 2	Allergic Conjunctivitis	-	-
NS2	Phase 2	Non-infectious Anterior Uveitis	-	-
Reproxalap Ophthalmic Solution (0.1%)	Phase 2	Dry Eye Syndrome	-	-

Regulatory Approvals

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply